** Hong Kong shares of BeiGene Ltd 6160.HK jump 8.2% to HK$174.8, their highest since December 2021, and on course for fourth consecutive session of gains
** Stock on track for the biggest one-day rise since February 21
** Shanghai-listed stock 688235.SS surges 9.7% to record high at 248 yuan
** U.S. stock ONC.O jumped 7.5% on Thursday
** Chinese oncology treatments developer said its total global revenues increased 78% y/y to $1.1 bln for Q4 and it was up 55% y/y to $3.8 bln for the full year of 2024
** Full year 2025 revenue guidance of $4.9 bln to $5.3 bln - Co
** Nomura, with "Buy" rating on the stock, says 4Q24 sales beat on balanced growth in the U.S., China, EU with higher FY25E sales guided
** Hang Seng Commerce & Industry Index .HSNC and healthcare index .HSCIH both fall 1.8%, Hang Seng Index .HSI eases 1.7%
** Hong Kong-listed stock up 53.4% YTD, Shanghai shares up 50.6%, US shares up 50.7%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。